Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer
Haid A, Kuehn T, Konstantiniuk P, Köberle-Wührer R, Knauer M, Kreienberg R, Zimmermann G. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol 2002; 28:705-10.
Nov 1, 2002Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer
Nov 1, 2002Eur J Surg Oncol 2002; 28:705-10
Haid A, Kuehn T, Konstantiniuk P, Köberle-Wührer R, Knauer Michael, Kreienberg R, Zimmermann G
Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann B, Bernhard J, Hsu Schmitz S, Schmid H. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32.
Aug 1, 2002Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
Aug 1, 2002European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann Beat, Bernhard J, Hsu Schmitz S-F, Schmid H-P
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British journal of cancer 2002; 86:1705-14.
Jun 5, 2002Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
Jun 5, 2002British journal of cancer 2002; 86:1705-14
Colleoni M, Collins J, Thürlimann Beat, Holmberg S B, Crivellari D, Beyerle C, Neumann R L A, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C-M, Litman H J, Castiglione-Gertsch M, Sauerbrei W, Gelber R D, Bonetti M, Coates A S, Schumacher M, Bastert G, German Breast Cancer Study Group
Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation
Haid A, Sturn H, Hergan K, Ammann M, Jasarevic Z, Peschina W, Fritzsche H, Burtscher J, Knauer M, Köberle-Wührer R, Zimmermann G. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat 2002; 73:31-6.
May 1, 2002Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation
May 1, 2002Breast Cancer Res Treat 2002; 73:31-6
Haid Anton, Sturn Heinz, Hergan Klaus, Ammann Maria, Jasarevic Zerina, Peschina William, Fritzsche Heinz, Burtscher Judit, Knauer Michael, Köberle-Wührer Roswitha, Zimmermann Gerhard
The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer
Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. Journal of cancer research and clinical oncology 2002; 128:153-60.
Mar 1, 2002The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer
Mar 1, 2002Journal of cancer research and clinical oncology 2002; 128:153-60
Huober Jens, Meyer A, Wagner U, Wallwiener D
Patients' estimation of overall treatment burden: why not ask the obvious?
Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro M, Swiss Group for Clinical Cancer Research. Patients' estimation of overall treatment burden: why not ask the obvious?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72.
Jan 1, 2002Patients' estimation of overall treatment burden: why not ask the obvious?
Jan 1, 2002Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72
Bernhard J, Maibach R, Thürlimann Beat, Sessa C, Aapro M S, Swiss Group for Clinical Cancer Research
Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression
Volkmann M, Zentgraf H, Fiehn W, Wallwiener D, Bastert G, Hänsel S, Ludwig J, Hajjar Y, Frey M, Gaugel D, Sinn H, Huober J. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 2002; 63:297-305.
Jan 1, 2002Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression
Jan 1, 2002Oncology 2002; 63:297-305
Volkmann Martin, Zentgraf Hanswalter, Fiehn Walter, Wallwiener Diethelm, Bastert Gunther, Hänsel Susanne, Ludwig Jochen, Hajjar Yaser, Frey Manfred, Gaugel Dirk, Sinn Hans-Peter, Huober Jens
Mammakarzinom in der Schwangerschaft
Huober J, Wallwiener D. Mammakarzinom in der Schwangerschaft. Geburtsh Frauenheilk 2002; 62:904-906.
Jan 1, 2002Mammakarzinom in der Schwangerschaft
Jan 1, 2002Geburtsh Frauenheilk 2002; 62:904-906
Huober Jens, Wallwiener D
Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Theraphie des Mammakarzinoms - Zeit zum Umdenken
Huober J, Wagner U, Wallwiener D. Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Theraphie des Mammakarzinoms - Zeit zum Umdenken. Geburtsh Frauenheilk 2002; 62:15-21.
Jan 1, 2002Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Theraphie des Mammakarzinoms - Zeit zum Umdenken
Jan 1, 2002Geburtsh Frauenheilk 2002; 62:15-21
Huober Jens, Wagner U, Wallwiener D
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.
Nov 1, 2001Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Nov 1, 2001Cancer 2001; 92:2247-58
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann Beat, Robertson J F, Nabholtz J M, Buzdar A, Investigators Committee Members
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9.
Nov 1, 2001Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Nov 1, 2001Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S B, Thürlimann Beat, Collins J, Lindtner J, Rudenstam C M, Price K, Gelber R D, Castiglione-Gertsch M, Coates A S, Gelber S, International Breast Cancer Study Group
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. Expert review of anticancer therapy 2001; 1:169-76.
Aug 1, 2001Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
Aug 1, 2001Expert review of anticancer therapy 2001; 1:169-76
Köberle Dieter, Thürlimann Beat
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H, Schlebusch H, Renke K, Huober J, Giffels P, Reinartz S, Köhler S, Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62.
May 1, 2001Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
May 1, 2001Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62
Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H J, Schlebusch H, Renke K, Huober Jens, Giffels P, Reinartz S, Köhler S, Wallwiener D
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6.
Mar 1, 2001High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Mar 1, 2001Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group
International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
Thürlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast cancer (Tokyo, Japan) 2001; 8:294-7.
Jan 1, 2001International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
Jan 1, 2001Breast cancer (Tokyo, Japan) 2001; 8:294-7
Thürlimann Beat
Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom
Huober J, Meyer A, Wagner U, Wallwiener D. Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom. Med. Welt 2001; 52:101-105.
Jan 1, 2001Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom
Jan 1, 2001Med. Welt 2001; 52:101-105
Huober Jens, Meyer A, Wagner U, Wallwiener D
Qualitätssicherung in der operativen Theraphie von Ovarialtumoren
Huober J, Meyer A, Wagner U, Wallwiener D. Qualitätssicherung in der operativen Theraphie von Ovarialtumoren. Med. Welt 2001; 52:184-187.
Jan 1, 2001Qualitätssicherung in der operativen Theraphie von Ovarialtumoren
Jan 1, 2001Med. Welt 2001; 52:184-187
Huober Jens, Meyer A, Wagner U, Wallwiener D
Identifying breast cancer patients at high risk for bone metastases
Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.
Dec 1, 2000Identifying breast cancer patients at high risk for bone metastases
Dec 1, 2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35
Colleoni M, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann Beat, Price K N, Castiglione-Gertsch M, Coates A S, Rudenstam C M
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57.
Nov 15, 2000Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Nov 15, 2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J F, Thürlimann Beat, von Euler M
Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer
Huober J, Nakamura S, Meyn R, Roth J, Mukhopadhyay T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. International journal of radiation oncology, biology, physics 2000; 48:1127-37.
Nov 1, 2000Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer
Nov 1, 2000International journal of radiation oncology, biology, physics 2000; 48:1127-37
Huober Jens, Nakamura S, Meyn R, Roth J A, Mukhopadhyay T